MaxCyte Net Borrowings vs Depreciation Analysis

MXCT Stock

USD 3.52 0.14 4.14%

MaxCyte financial indicator trend analysis is infinitely more than just investigating MaxCyte recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MaxCyte is a good investment. Please check the relationship between MaxCyte Net Borrowings and its Depreciation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.

Net Borrowings vs Depreciation

Net Borrowings vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MaxCyte Net Borrowings account and Depreciation. At this time, the significance of the direction appears to have pay attention.

The correlation between MaxCyte's Net Borrowings and Depreciation is -0.86. Overlapping area represents the amount of variation of Net Borrowings that can explain the historical movement of Depreciation in the same time period over historical financial statements of MaxCyte, assuming nothing else is changed. The correlation between historical values of MaxCyte's Net Borrowings and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Borrowings of MaxCyte are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Net Borrowings i.e., MaxCyte's Net Borrowings and Depreciation go up and down completely randomly.

Correlation Coefficient

-0.86

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.

Depreciation

Depreciation indicates how much of MaxCyte value has been used up. For tax purposes MaxCyte can deduct the cost of the tangible assets it purchases as business expenses. However, MaxCyte must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from MaxCyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MaxCyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.At this time, MaxCyte's Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.76 in 2024, whereas Enterprise Value Multiple is likely to drop (10.89) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.0M	126.9K	145.9K	138.6K
Depreciation And Amortization	1.4M	2.7M	4.2M	4.4M

Interest Expense Depreciation And Amortization

MaxCyte fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Stockholder Equity	Other Liab	Net Tangible Assets
Total Assets		0.83	0.93	0.86	1.0	0.93	0.83	-0.64	-0.92	-0.4	0.81	0.82	0.45	0.98	0.8	0.9	0.84	0.9	0.95	0.91	0.99	-0.38	0.79	0.95	0.83	0.99
Short Long Term Debt Total	0.83		0.94	0.75	0.81	0.96	0.66	-0.42	-0.95	-0.36	0.7	0.94	0.26	0.73	0.68	0.75	0.99	0.97	0.87	0.97	0.75	-0.34	0.68	0.75	0.96	0.85
Other Current Liab	0.93	0.94		0.88	0.92	0.95	0.83	-0.62	-0.99	-0.37	0.83	0.9	0.33	0.87	0.78	0.86	0.95	0.98	0.91	0.99	0.88	-0.42	0.83	0.87	0.9	0.92
Total Current Liabilities	0.86	0.75	0.88		0.86	0.79	0.95	-0.64	-0.89	-0.26	0.76	0.65	0.26	0.86	0.87	0.96	0.78	0.8	0.84	0.86	0.87	-0.45	0.96	0.94	0.68	0.81
Total Stockholder Equity	1.0	0.81	0.92	0.86		0.91	0.83	-0.64	-0.9	-0.4	0.8	0.8	0.47	0.99	0.79	0.89	0.81	0.88	0.94	0.89	0.99	-0.37	0.78	0.95	0.81	0.99
Property Plant And Equipment Net	0.93	0.96	0.95	0.79	0.91		0.71	-0.46	-0.95	-0.49	0.71	0.94	0.44	0.85	0.72	0.84	0.95	0.98	0.93	0.96	0.86	-0.3	0.7	0.86	0.97	0.94
Current Deferred Revenue	0.83	0.66	0.83	0.95	0.83	0.71		-0.57	-0.81	-0.2	0.68	0.51	0.2	0.86	0.93	0.9	0.71	0.7	0.83	0.8	0.87	-0.59	0.94	0.88	0.57	0.75
Net Debt	-0.64	-0.42	-0.62	-0.64	-0.64	-0.46	-0.57		0.64	-0.1	-0.94	-0.52	-0.09	-0.64	-0.37	-0.53	-0.43	-0.56	-0.41	-0.57	-0.63	0.25	-0.65	-0.59	-0.36	-0.63
Retained Earnings	-0.92	-0.95	-0.99	-0.89	-0.9	-0.95	-0.81	0.64		0.32	-0.84	-0.9	-0.29	-0.84	-0.77	-0.87	-0.95	-0.98	-0.89	-0.99	-0.86	0.36	-0.84	-0.87	-0.89	-0.91
Accounts Payable	-0.4	-0.36	-0.37	-0.26	-0.4	-0.49	-0.2	-0.1	0.32		-0.05	-0.43	-0.86	-0.36	-0.15	-0.42	-0.3	-0.42	-0.39	-0.31	-0.36	0.02	-0.05	-0.39	-0.52	-0.45
Cash	0.81	0.7	0.83	0.76	0.8	0.71	0.68	-0.94	-0.84	-0.05		0.75	0.17	0.76	0.53	0.68	0.7	0.8	0.64	0.8	0.77	-0.31	0.75	0.73	0.63	0.81
Non Current Assets Total	0.82	0.94	0.9	0.65	0.8	0.94	0.51	-0.52	-0.9	-0.43	0.75		0.39	0.7	0.48	0.68	0.9	0.96	0.77	0.9	0.72	-0.14	0.55	0.72	0.96	0.87
Non Currrent Assets Other	0.45	0.26	0.33	0.26	0.47	0.44	0.2	-0.09	-0.29	-0.86	0.17	0.39		0.44	0.18	0.45	0.19	0.36	0.36	0.25	0.44	0.17	0.09	0.44	0.46	0.5
Cash And Short Term Investments	0.98	0.73	0.87	0.86	0.99	0.85	0.86	-0.64	-0.84	-0.36	0.76	0.7	0.44		0.82	0.89	0.74	0.8	0.93	0.83	1.0	-0.42	0.8	0.95	0.72	0.95
Net Receivables	0.8	0.68	0.78	0.87	0.79	0.72	0.93	-0.37	-0.77	-0.15	0.53	0.48	0.18	0.82		0.87	0.74	0.68	0.87	0.78	0.83	-0.47	0.9	0.84	0.6	0.7
Common Stock Shares Outstanding	0.9	0.75	0.86	0.96	0.89	0.84	0.9	-0.53	-0.87	-0.42	0.68	0.68	0.45	0.89	0.87		0.76	0.81	0.89	0.84	0.9	-0.3	0.87	0.97	0.73	0.85
Non Current Liabilities Total	0.84	0.99	0.95	0.78	0.81	0.95	0.71	-0.43	-0.95	-0.3	0.7	0.9	0.19	0.74	0.74	0.76		0.96	0.89	0.98	0.77	-0.4	0.74	0.77	0.93	0.83
Inventory	0.9	0.97	0.98	0.8	0.88	0.98	0.7	-0.56	-0.98	-0.42	0.8	0.96	0.36	0.8	0.68	0.81	0.96		0.87	0.98	0.82	-0.29	0.73	0.82	0.95	0.91
Other Current Assets	0.95	0.87	0.91	0.84	0.94	0.93	0.83	-0.41	-0.89	-0.39	0.64	0.77	0.36	0.93	0.87	0.89	0.89	0.87		0.91	0.94	-0.43	0.77	0.92	0.85	0.92
Total Liab	0.91	0.97	0.99	0.86	0.89	0.96	0.8	-0.57	-0.99	-0.31	0.8	0.9	0.25	0.83	0.78	0.84	0.98	0.98	0.91		0.85	-0.43	0.82	0.84	0.91	0.9
Total Current Assets	0.99	0.75	0.88	0.87	0.99	0.86	0.87	-0.63	-0.86	-0.36	0.77	0.72	0.44	1.0	0.83	0.9	0.77	0.82	0.94	0.85		-0.42	0.81	0.96	0.74	0.96
Short Term Debt	-0.38	-0.34	-0.42	-0.45	-0.37	-0.3	-0.59	0.25	0.36	0.02	-0.31	-0.14	0.17	-0.42	-0.47	-0.3	-0.4	-0.29	-0.43	-0.43	-0.42		-0.5	-0.34	-0.22	-0.3
Common Stock	0.79	0.68	0.83	0.96	0.78	0.7	0.94	-0.65	-0.84	-0.05	0.75	0.55	0.09	0.8	0.9	0.87	0.74	0.73	0.77	0.82	0.81	-0.5		0.85	0.58	0.71
Other Stockholder Equity	0.95	0.75	0.87	0.94	0.95	0.86	0.88	-0.59	-0.87	-0.39	0.73	0.72	0.44	0.95	0.84	0.97	0.77	0.82	0.92	0.84	0.96	-0.34	0.85		0.74	0.92
Other Liab	0.83	0.96	0.9	0.68	0.81	0.97	0.57	-0.36	-0.89	-0.52	0.63	0.96	0.46	0.72	0.6	0.73	0.93	0.95	0.85	0.91	0.74	-0.22	0.58	0.74		0.86
Net Tangible Assets	0.99	0.85	0.92	0.81	0.99	0.94	0.75	-0.63	-0.91	-0.45	0.81	0.87	0.5	0.95	0.7	0.85	0.83	0.91	0.92	0.9	0.96	-0.3	0.71	0.92	0.86

Click cells to compare fundamentals

MaxCyte Account Relationship Matchups

MaxCyte fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.0M	51.8M	284.1M	286.7M	268.3M	281.7M
Short Long Term Debt Total	7.2M	7.0M	5.7M	16.1M	18.7M	19.7M
Other Current Liab	3.6M	5.2M	6.5M	8.3M	9.7M	10.2M
Total Current Liabilities	9.3M	11.6M	15.6M	15.4M	17.9M	9.7M
Total Stockholder Equity	13.6M	33.2M	262.9M	254.0M	232.2M	243.8M
Property Plant And Equipment Net	5.5M	6.5M	13.4M	33.6M	34.8M	36.5M
Current Deferred Revenue	3.2M	4.8M	6.7M	6.7M	5.1M	3.5M
Net Debt	(8.0M)	(11.8M)	(42.1M)	5.0M	(27.8M)	(26.4M)
Retained Earnings	(83.4M)	(95.2M)	(114.3M)	(137.9M)	(175.8M)	(167.0M)
Accounts Payable	2.1M	890.2K	1.8M	292K	743K	705.9K
Cash	15.2M	18.8M	47.8M	11.1M	46.5M	48.8M
Non Current Assets Total	5.5M	6.5M	13.7M	34.4M	78.1M	82.0M
Cash And Short Term Investments	16.7M	34.8M	255.0M	227.3M	168.3M	176.7M
Net Receivables	3.2M	5.2M	6.9M	11.2M	5.8M	4.3M
Common Stock Shares Outstanding	56.4M	69.5M	90.6M	101.7M	103.3M	66.8M
Liabilities And Stockholders Equity	30.0M	51.8M	284.1M	286.7M	268.3M	281.7M
Non Current Liabilities Total	7.0M	6.9M	5.6M	17.3M	18.3M	19.2M
Inventory	3.7M	4.3M	5.2M	8.6M	12.2M	12.8M
Other Current Assets	797.1K	1.0M	3.3M	6.0M	3.9M	4.1M
Total Liab	16.4M	18.6M	21.2M	32.7M	36.1M	37.9M
Total Current Assets	24.5M	45.3M	270.4M	252.3M	190.2M	199.7M
Short Term Debt	508.9K	672.6K	527.2K	157K	1.5M	845.8K
Common Stock	574K	773.8K	1.0M	1.0M	1.0M	542.8K
Other Stockholder Equity	96.4M	127.7M	376.2M	390.8M	406.9M	222.4M
Other Liab	338.1K	646.6K	450.2K	1.3M	1.5M	1.6M
Net Tangible Assets	13.6M	33.2M	262.9M	254.0M	292.1M	306.7M
Common Stock Total Equity	574K	773.8K	1.0M	1.0M	1.2M	807.8K
Capital Lease Obligations	2.3M	2.0M	5.7M	16.1M	18.7M	19.7M
Net Invested Capital	18.5M	38.1M	262.9M	254.0M	232.2M	133.2M
Property Plant And Equipment Gross	5.5M	6.5M	7.7M	23.7M	45.0M	47.3M
Non Current Liabilities Other	338.1K	646.6K	450.2K	1.3M	283K	268.9K
Net Working Capital	15.1M	33.6M	254.8M	236.8M	172.3M	118.2M
Property Plant Equipment	5.5M	6.5M	13.4M	23.7M	27.3M	28.6M
Short Term Investments	1.5M	16.0M	207.3M	216.3M	121.8M	103.8M
Capital Stock	574K	773.8K	1.0M	1.0M	1.0M	905.1K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC